Results 91 to 100 of about 50,545 (304)

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Suicide attempt and paranoia persisting for 28 days following heavy delta-9-tetrahydrocannabinolic acid and tetrahydrocannabinol use: A case report. [PDF]

PCN Rep
Abstract Background Cannabis contains various cannabinoids, with Δ9‐tetrahydrocannabinol (Δ9‐THC) being the primary psychoactive compound. A non‐psychoactive precursor called Δ9‐tetrahydrocannabinolic acid (THC‐A) is converted to Δ9‐THC slowly over time or rapidly when heated. Cannabis use is linked to psychotic outcomes, with increased risk associated
Greer D, Dey P, Kulig CE.
europepmc   +2 more sources

Supplementary Tables 1-2, Figure 1 from Cannabinoids Inhibit Glioma Cell Invasion by Down-regulating Matrix Metalloproteinase-2 Expression

, 2023
Cristina Blázquez, María Salazar, Arkaitz Carracedo, Mar Lorente, Ainara Egia, Luis González‐Feria, Amador Haro, Guillermo Velasco, Manuel Guzmán   +8 more
openalex   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Exploiting modern cannabinoid pharmacology for therapeutic gain? [PDF]

, 2012
James M. Ritter
openalex   +1 more source

Endocannabinoid system gene expression in mesocorticolimbic brain regions of individuals with alcohol use disorder: A descriptive study

Addiction, EarlyView.
Abstract Aims To describe differences in the expression of genes encoding cannabinoid receptors (CNR1, CNR2), the associated receptor GRP55 and the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGLL) between individuals with alcohol use disorder (AUD) and controls in key mesocorticolimbic brain regions.
María Salud García‐Gutiérrez, Abraham Bailén Torregrosa, Francisco Navarrete, Auxiliadora Aracil‐Fernández, Gabriel Rubio, Jorge Manzanares   +5 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges

Discover Oncology
For centuries, cannabinoids have been utilized for their medicinal properties, particularly in Asian and South-Asian countries. Cannabis plants, known for their psychoactive and non-psychoactive potential, were historically used for spiritual and ...
Manal Bint Faiz, Faiza Naeem, Muhammad Irfan, Muhammad Adeel Aslam, Leticia M. Estevinho, Dilek Arslan Ateşşahin, Asma M. Alshahrani, Daniela Calina, Khushbukhat Khan, Javad Sharifi-Rad   +9 more
doaj   +1 more source

Addiction‐related problems in Japan: A regional perspective

Addiction, EarlyView.
Abstract Japan's addiction landscape appears paradoxical. The lifetime use of illicit drugs is among the lowest in Organisation for Economic Cooperation and Development countries, but harm from alcohol, tobacco, and gambling ranks among the world's highest.
Soichiro Ide, Yoko Nishitani, Masahiko Sumitani, Masabumi Minami, Tadashi Isa, Masako Iseki, Michiko Ohkura, Hitoshi Okamoto, Tetsuro Kikuchi, Yuko Sekino, Hidehiko Takahashi, Kenji Takeuchi, Atsumi Nitta, Takeshi Honjo, Hiroshi Matsumoto, Tsuyoshi Miyakawa, Toshiya Murai, Toshihiko Matsumoto, Kazuyuki Nakagome, Kazutaka Ikeda   +19 more
wiley   +1 more source

Trends in fentanyl‐containing drug samples seized by law enforcement agencies across Canada

Addiction, EarlyView.
Abstract Background and aims Canada's drug toxicity crisis has been largely attributed to a volatile fentanyl‐dominated unregulated drug supply with increasing reports of fentanyl detected in combination with benzodiazepines, stimulants and xylazine.
Shaleesa Ledlie, Ria Garg, Pamela Leece, Gillian Kolla, Elaine Hyshka, Mina Tadrous, Tara Gomes   +6 more
wiley   +1 more source